Key Takeaways
- Flyrcado, GEHC’s new cardiac PET imaging agent, has CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate and is expected to generate $30m in 2025 and up to $500m by 2028.
GE HealthCare’s CEO has high expectations for Flyrcado, a positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting...